We previously examined the relationship between acquired resistance to EGFR-TKI and TNF sensitivity in NSCLC cell lines and found that, with regard to the EGFR-sensitive mutation, a gefitinib-resistant cell line was ~67 times more sensitive to TNF-α than the gefitinib-sensitive cell line. The gene discussed is TNF; the disease is non-small cell lung carcinoma.